Prescription drug · BLA
Ilumya (tildrakizumab-asmn) NDC 47335-177
Tildrakizumab 100 mg/mL · Injection, Solution · Subcutaneous · Sun Pharmaceutical Industries, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 47335-177-01 | 47335017701 | 1 mL in 1 SYRINGE, GLASS (47335-177-01)Marketed from Aug 6, 2018 · Sample package | |
| 47335-177-10 | 47335017710 | 1 mL in 1 CARTON (47335-177-10)Marketed from Aug 6, 2018 · Sample package | |
| 47335-177-95 | 47335017795 | 1 mL in 1 CARTON (47335-177-95)Marketed from Aug 6, 2018 | |
| 47335-177-96 | 47335017796 | 1 mL in 1 SYRINGE, GLASS (47335-177-96)Marketed from Aug 6, 2018 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ilumya
- Generic name (nonproprietary)
- tildrakizumab-asmn
- Active ingredients
- Tildrakizumab — 100 mg/mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761067
- Marketing start
- Listing expires
- Other FDA classes
- Interleukin-23 Antagonists (Mechanism)
- Identifiers
- Product ID 47335-177_edc3f29f-1b74-4e56-ad3e-b6f213ce56d2SPL ID edc3f29f-1b74-4e56-ad3e-b6f213ce56d2SPL set ID c6a322bb-51b9-4f0e-8642-62a9682ffcdeRxCUI 2053453, 2053458UNII DEW6X41BEK
- Pharmacologic class
- Interleukin-23 Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N447335017701followed by a unit qualifier and the quantityPackage 47335-0177-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
ILUMYA ® is indicated for the treatment of moderate-to-severe plaque psoriasis in aduts who are candidates for systemic therapy or phototherapy. ILUMYA is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1 )
Excerpt only. Read the full label for complete information.